

UCLA

UCLA Previously Published Works

Title

Focused CRISPR-Cas9 genetic screening reveals USO1 as a vulnerability in B-cell acute lymphoblastic leukemia

Permalink

<https://escholarship.org/uc/item/8wv4467q>

Journal

Scientific Reports, 11(1)

ISSN

2045-2322

Authors

Jaiswal, Amit Kumar

Truong, Hellen

Tran, Tiffany M

et al.

Publication Date

2021

DOI

10.1038/s41598-021-92448-w

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed



OPEN

Focused CRISPR-Cas9 genetic screening reveals *USO1* as a vulnerability in B-cell acute lymphoblastic leukemia

Amit Kumar Jaiswal¹, Hellen Truong¹, Tiffany M. Tran^{1,2}, Tasha L. Lin³, David Casero⁴, Michael O. Alberti⁵ & Dinesh S. Rao^{1,6,7}✉

Post-transcriptional gene regulation, including that by RNA binding proteins (RBPs), has recently been described as an important mechanism in cancer. We had previously identified a set of RBPs that were highly dysregulated in B-cell acute lymphoblastic leukemia (B-ALL) with *MLL* translocations, which carry a poor prognosis. Here, we sought to functionally characterize these dysregulated RBP genes by performing a focused CRISPR dropout screen in B-ALL cell lines, finding dependencies on several genes including *EIF3E*, *EPRS* and *USO1*. Validating our findings, CRISPR/Cas9-mediated disruption of *USO1* in *MLL*-translocated B-ALL cells reduced cell growth, promoted cell death, and altered the cell cycle. Transcriptomic analysis of *USO1*-deficient cells revealed alterations in pathways related to mTOR signaling, RNA metabolism, and targets of MYC. In addition, *USO1*-regulated genes from these experimental samples were significantly and concordantly correlated with *USO1* expression in primary samples collected from B-ALL patients. Lastly, we found that loss of *Uso1* inhibited colony formation of *MLL*-transformed in primary bone marrow cells from *Cas9-EGFP* mice. Together, our findings demonstrate an approach to performing focused sub-genomic CRISPR screens and highlight a putative RBP vulnerability in *MLL*-translocated B-ALL, thus identifying potential therapeutic targets in this disease.

B-ALL is the most common type of leukemia in the pediatric population, and is characterized by a number of recurrent chromosomal rearrangements^{1–4}. Among these, the t(4;11) *MLL-AF4* (*KMT2A-AFF1*) translocation gives rise to a highly aggressive form of B-ALL^{5,6}. Patients with *MLL*-rearranged B-ALL have a dismal prognosis, with 5-year event-free survival rates hovering at 33.6% for infants⁷ and 50% for older children and adults⁸. Most of these patients are resistant to conventional treatment with chemotherapy and steroids⁹, with bone marrow transplantation being the only curative therapeutic alternative¹⁰. Although recent developments such as CAR-T therapy¹¹ and anti-CD19 based therapy such as Blinatumomab¹² have raised hope for such patients¹³, antigen escape and lineage infidelity in *MLL*-translocated leukemia have proved problematic¹⁴. Therefore, there is an urgent need to better characterize potential therapeutic targets with high specificity.

The *MLL-AF4* translocation engenders a unique transcriptional profile, as the fusion protein juxtaposes a histone methyltransferase (*MLL*, also known as *KMT2A*) with a protein that is involved in transcriptional regulation (*AF4*, or *AFF1*). Recently our lab carried out a study examining the expression of RBPs in B-ALL¹⁵, including both known and predicted RBPs¹⁶. In our analysis, we identified 36 RBPs that are highly upregulated in *MLL-AF4* translocated B-ALL¹⁵. To study the importance of these genes in B-ALL, we implemented the powerful gene editing technique, CRISPR/Cas9, to perform a rapid and medium-throughput assessment of gene function. Genome wide CRISPR/Cas9 screens on AML cell lines have identified multiple gene targets critical for cell proliferation and survival¹⁷, but similar studies have not been performed in *MLL-AF4* translocated B-ALL.

¹Department of Pathology and Laboratory Medicine, David Geffen School of Medicine At UCLA, Los Angeles, CA 90095, USA. ²Molecular, Cellular and Integrative Physiology Graduate Program, UCLA, Los Angeles, USA. ³Department of Internal Medicine, Division of Hematology/Oncology, UCLA, Los Angeles, USA. ⁴F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA. ⁵Department of Pathology, Washington University, St. Louis, USA. ⁶Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, USA. ⁷Broad Stem Cell Research Center, UCLA, Los Angeles, USA. ✉email: drao@mednet.ucla.edu

In the present study, we performed a sub-genomic CRISPR/Cas9 dropout screen using 36 highly upregulated RBPs in primary human B-ALL and identified several novel vulnerabilities that included three putative RBPs. Of these, *USO1*, a putative RBP and a known regulator of vesicular transport, was identified as a *MLL-AF4* target gene. CRISPR/Cas9-mediated disruption of *USO1* significantly altered cell growth and the cell cycle in B-ALL cell lines; as well as inhibited the colony forming potential of *MLL*-transformed primary murine bone marrow cells. *USO1* depletion regulated the expression of genes related to mTOR signaling, metabolism of RNA, and *MYC* targets. Together, our studies provide a comprehensive rubric to functionally evaluate putative targets identified from expression profiling, and the identification of a novel potential target in *MLL*-rearranged leukemia.

Results

CRISPR/Cas9 screen identifies potential vulnerabilities in *MLL-AF4* leukemic cell growth. Previously, we identified 36 putative RBPs that were significantly dysregulated in primary human *MLL*-rearranged B-ALL¹⁵. To directly query the functional relevance of RBP dysregulation in *MLL*-rearranged B-ALL, we performed a sub-genomic CRISPR screen (Fig. 1A). The library consisted of sgRNAs targeting 36 RBP genes, 12 “positive control” genes, representing known vulnerabilities in *MLL*-translocated leukemia¹⁷, and 28 non-targeting (NT) sgRNAs. The screen was designed using a two-vector lentiviral system. First, B-ALL cells with and without *MLL-AF4* translocation (SEM and NALM6, respectively) were stably transduced with a *Cas9-P2A-EGFP* transgene, followed by FACS sorting of the transduced cells based on GFP positivity. Next, Cas9-GFP⁺ SEM and NALM6 cells were transduced at a MOI of < 0.3 with the pooled sgRNA lentiviral library, comprised of 268 unique sgRNAs. Cells were subsequently FACS sorted 48 h following transduction for GFP and tRFP double positivity (Fig. 1B). 2×10^6 cells were sorted, of which 10^6 cells were used to isolate genomic DNA for the reference (REF) libraries and the remainder were cultured to maintain $3700 \times$ coverage until collection of genomic DNA for the depletion (DEP) libraries following 28 days in culture. Experimental replicates of REF and DEP libraries showed a high degree of concordance in abundance of both individual sgRNAs and for total sgRNAs per gene (Supplementary Fig. 1D & 1E). In addition, the SEM and NALM6 REF libraries showed overall similar rates of individual gRNA incorporation, as measured by the abundance of each gRNA in each of the cell lines and biological replicates (Supplementary Fig. 1F). As expected, a majority of “positive control” genes, including *BCL2*, *COA5*, *CDK6*, and *MYC*, were significantly downregulated in the DEP libraries in both NALM6 and SEM cells. This is not surprising as many of these are known oncogenic genes, particularly in B-ALL. Non-targeting or “negative control” sgRNAs were consistently unchanged between the REF and DEP libraries (Fig. 1C, D). Comparing the results across cell lines, we found that sgRNAs targeting three genes, *USO1*, *EIF3E* and *EPRS* were significantly depleted in SEM cells ($p < 0.001$), when compared to NALM6 cells (Fig. 1E). Interestingly, sgRNA dropout in general was more readily observed in SEM cells than in NALM6 cells, potentially due to the fact that these genes were selected based on high expression in patient B-ALL samples with *MLL-AF4* translocation. Of these three genes, *USO1* had previously been detected in a genome-wide CRISPR screen as a vulnerability in MV-4-11 cells, which also harbor the *MLL-AF4* fusion gene¹⁷.

***USO1* is directly regulated by *MLL-AF4*.** *USO1*, *EPRS* and *EIF3E* expression was assessed in, SEM, RS4;11 (another *MLL-AF4* translocated cell line), and NALM6 (Supplementary Fig. 2A & 2B). To query their regulation by the *MLL-AF4* fusion protein, we analyzed their expression following inhibition with I-BET151¹⁸, a BRD4 BET domain inhibitor, MI-503 menin-*MLL1* inhibitor¹⁹ and EPZ5676, a DOT1L inhibitor²⁰, all known to inhibit *MLL*-dependent gene expression regulation. With increasing doses of I-BET151, MI-503 and EPZ5676 there was a decrease in the *USO1* mRNA expression level in SEM (Fig. 2A), and RS4;11 cells (Fig. 2B), but not in NALM6 cells (Fig. 2C as well as Supplementary Fig. 2C, 2D & 2E), suggesting that *USO1* expression is *MLL-AF4* dependent. A consistent reduction in *EIF3E* and *EPRS* was not observed in the *MLL* translocated cell lines. We further queried the *MLL* dependence of *USO1* by over-expressing the *MLL-AF4* transgene²¹ in murine bone marrow cells. Western Blot and RT-qPCR analysis showed upregulation of *MLL1* and *USO1* in *MLL-AF4* transduced cells compared to control cells (Fig. 2D and Supplementary Fig. 2F). Using publicly available data²¹, we found that the *USO1* and *EIF3E* genes demonstrated multiple *MLL-AF4* binding sites within the 5'UTR, the first exon, and the first intron (Fig. 2E and Supplementary Fig. 2G). In contrast, the *EPRS* gene did not show strong *MLL-AF4* binding sites (Supplementary Fig. 2H). *EIF3e* and *EPRS* were previously reported to be “common essential genes”, per the depmap portal²², whereas *USO1* was not such a gene, suggesting its potential utility as a novel clinical target. To confirm our findings of *USO1* dependence on *MLL-AF4*, we designed chromatin immunoprecipitation (ChIP) experiments, designing primers for the regulatory regions of *USO1* including the 5' UTR within the first exon. We found significant enrichment of the *USO1* regulatory regions in both the *MLL1* and *AF4* pulldowns (Fig. 2F). Treatment of the cells with I-BET151 inhibited the association of both *MLL1* and *AF4* with the promoter region of *USO1* (Fig. 2G). Together, these findings indicate that *USO1* is a direct target of the *MLL-AF4* transcriptional program.

***USO1* depletion alters B-ALL cell proliferation, survival and cell cycle.** *USO1* expression is upregulated in several types of cancer including B-ALL with *MLL-AF4* translocations²³⁻²⁵. To characterize the functional role of *USO1* in B-ALL suggested by our CRISPR screen, we utilized the previously mentioned two-vector lentivirus system to transduce SEM cells with three different lentiviral constructs containing sgRNAs that target different regions of the *USO1* gene (Fig. 3A, B). We found that two sgRNAs (sg2 and sg3) caused a significant downregulation of *USO1* protein and mRNA expression by approximately 80% in SEM cells (Fig. 3C, D). Cas9-mediated frameshift mutation in *USO1* was confirmed using TIDE assay²⁶ (Supplementary Fig. 3A). The lack of complete ablation was a reproducible finding in all cell lines we tested, as multiple single-cell cloning experiments failed to produce cells with complete knockout and multiple bulk cultures experiments showed




Figure 1. Sub-genomic CRISPR screen identifies functionally important genes in *MLL-AF4*-translocated B-ALL. **(A)** Schematic of sub-genomic CRISPR screen. **(B)** FACS contour plots reflecting sorting strategy based on high expression of Cas9 (GFP) and pooled guide RNA library (tRFP) in B-ALL cell lines. **(C, D)** Variance-stabilized normalized abundance for individual sgRNAs in Reference (Ref; x-axis) and Depletion (Dep; y-axis) libraries in SEM (C) and NALM6 (D) cell lines. Dots are colored by sgRNA class (dark yellow: positive controls; black: non-targeting negative controls; teal: targeting sgRNAs). Dots highlighted with a red border were classified as differentially abundant (Log_2 fold change [Log_2FC] > 1, Wald adjusted p value < 0.001). Genes with three or more differential sgRNAs are highlighted in the inset and colored by class. **(E)** Differential expression of sgRNAs aggregated by gene (Log_2FC gene total), in NALM6 (x-axis) vs SEM (y-axis) cell lines. Dots in the upper left represent genes with a higher fold-change in SEM cells, while those on the lower right represent genes with a higher fold-change in NALM6 cells. Dots are colored by sgRNA class and sized according to the number of individual sgRNAs that showed significant differential representation in the Dep libraries.

retained partial expression of < 25%. Nonetheless, we observed that bulk *USO1*-depleted SEM cells from sg2 and sg3 showed reduced proliferation by MTS assay (Fig. 3E). Since sg3 showed near-total ablation of *USO1* protein expression, we later used sg3 to target *USO1* in RS4;11 cells (Supplementary Fig. 3B & 3C), finding downregulation, but not complete depletion, of *USO1* protein. Propidium Iodide (PI) based cell cycle analysis on *USO1*-depleted cells showed an increased percentage of cells in the G0/G1 stage, suggesting cell cycle arrest, and more cells in Sub-G0/G1, suggesting increased apoptosis (Fig. 3F, G). Increased cell death was also observed in the *USO1*-depleted cells by Annexin V staining (Fig. 3H, I). Interestingly, *USO1*-depleted cells treated with I-BET151 also showed increased cell cycle arrest and apoptosis (Supplementary Fig. 3D–3G), suggesting an additive effect with this inhibitor of BRD4. To confirm our findings in an orthogonal system, we introduced siRNAs targeting *USO1* using nucleofection. In these short-term assays, we found that there was partial reduction of *USO1* mRNA, as expected with siRNA-mediated knockdown (Supplementary Fig. 4A) and increased Annexin V staining (Supplementary Fig. 4B, C). There were also increased cells in Sub-G0/G1 and a modest reduction in cell proliferation as measured by the MTS assay (Supplementary Fig. 4E, F). Together, these observations confirm the importance of *USO1* in regulation of cell cycle and survival of B-ALL cells.




Figure 2. Dependence of RBP gene expression on MLL-AF4 translocation. (A–C) Effect of I-BET 151 and MI-503 treatment on mRNA expression levels of *USO1*, *EPRS* and *EIF3E*, measured by RT-qPCR, in SEM (A), RS4;11 (B), and NALM6 (C). The cells were treated with increasing concentrations of I-BET151 (DMSO only, 0.5, 1 and 2 μM) or with increasing concentrations of the menin inhibitor, MI-503 (DMSO only, 0.12, 0.25, and 0.5 μM). RT-qPCR was performed with an optimized set of primers, normalized to 18S, and then represented as fold-change from vehicle-treated control. **D.** Western blot analysis of murine bone marrow cells with and without transduction with MLL-Af4 (WT versus MLL-Af4), for MLL1 (top), USO1 (middle) and β-actin (lower). **(E)** UCSC genome browser shot of the *USO1* locus showing the *MLL-AF4* ChIP site(s), as identified from the ChIP-Seq data from Lin et al.²¹, in a gene expression regulatory region; *Courtesy: UCSC Genome Browser*. Shown are the H3K27Ac track in hematopoietic K562 cells (Blue), and MLL-AF4 binding sites represented as a grayscale chart, with black indicating the highest score/highest number of reads from the dataset. **(F)** Chromatin immunoprecipitation with indicated antibodies (MLL1, AF4, and RNA Pol II), followed by qPCR (ChIP-qPCR) analysis for quantitation of bound *USO1* promoter/regulatory region to MLL1 and AF4 pulldown samples. Shown is the fold-enrichment for qPCR of the *USO1* regulatory site over background (t test; * $P < 0.05$) **(G)** SEM cells treated with 1 μM of I-BET151 for 48 h. and subjected to ChIP qPCR with MLL1 and AF4 antibodies as in (F) (t test; * $P < 0.05$).




Figure 3. Depletion of *USO1* leads to decreased cell growth, cell cycle arrest and increased apoptosis. (A) Schematic representation of the pLKO5.sgRNA.EFS.tRFP lentiviral vector. Abbreviations, hU6, human U6 promoter; sgRNA, short guide RNA; sg scaf, sgRNA scaffold; tRFP, turbo red fluorescent protein. (B) Sample FACS plots of SEM cells transduced sequentially with Cas9 vector and sgRNA containing vector. Left, non-transduced SEM cells; middle, transduced with pLentiCas9-GFP; right, cells transduced with both pLenti-Cas9-GFP and pLKO5 vector containing *USO1*-targeting sgRNA. (C) Western blot for *USO1* in SEM cells following CRISPR/Cas9-mediated disruption of the *USO1* gene using three different sgRNAs (sg1-3) and NT, non-targeting sgRNAs. (D) RT-qPCR measurement of *USO1* in control (NT) and *USO1* (sg2 & sg3) SEM cells (t test; ** $P < 0.01$; **** $P < 0.0001$) (E) MTS assay to study the cell growth of *USO1*-depleted cells (sg2 & sg3), measured as Absorbance at 490 nm (t test; ** $P < 0.01$; *** $P < 0.001$). (F, G) Cell cycle analysis using propidium iodide (PI) staining of control cells and *USO1*-depleted cells (F) and quantitation of cells from cell cycle analysis (Two-way Anova with Bonferroni correction; * $P < 0.05$; **** $P < 0.0001$). (H, I) FACS plots of Annexin V positivity in control versus *USO1*-depleted cells (H), Quantitation of cells with Annexin V positivity (t test; ** $P < 0.01$) (I).

USO1 impacts pathways related to cellular proliferation and RNA homeostasis. To evaluate the effect of *USO1* depletion on the overall gene expression pattern in B-ALL cells, we performed RNA-Seq on SEM cells that were depleted of *USO1* by CRISPR/Cas9 (three biological replicates per condition). Following differential expression analysis of *USO1*-depleted and control cells, we utilized the Metascape algorithm and Gene set enrichment analysis (GSEA) to assess pathway enrichment^{27,28}. We found that significantly downregulated pathways included MTOR, ERB2, and Hallmark Hypoxia, while upregulated terms included Metabolism of RNA and Hallmark MYC targets (Fig. 4A and Supplementary Fig. 5A). Analysis of Gene Ontology -Molecular Function gene sets revealed positive enrichment of several gene sets related to RNA homeostasis in the *USO1*-depleted cells (Supplementary Fig. 5B). Selected examples of up- and down regulated genes ($\log_2FC > 1.5$ and P_{adj} value < 0.01), from the enriched pathway identified by GSEA are highlighted in the Volcano plot for RNA-seq data (Fig. 4B). RT-qPCR was used to confirm these same significantly upregulated (*TFRC*, *MRPS12*, and *PSMD1*) (Fig. 4C) and downregulated genes (*BAP1P2*, *ABCA1* and *BTAF1*) (Fig. 4D) in *USO1*-depleted SEM cells. This led us to hypothesize that there were alterations in expression and activation of MTOR in *USO1*-depleted cells using western blotting. We observed there was a mild downregulation of p-MTOR (Ser2481) in the *USO1*-depleted cells (Fig. 4E). Hence, it appears that *USO1* regulates several pathways that are known to play a role in cell survival and cell death²⁹.

To assess whether the gene expression changes caused by *USO1*-depletion had any clinical relevance, we turned to the Target Phase II Acute lymphoblastic leukemia dataset, accessed via the cBioPortal interface^{30,31}. We calculated correlation coefficients between *USO1* and 24,278 genes detected by RNA-seq in 203 samples from 154 patients. Using a cut-off q value of 0.001, we then overlapped genes up- or down-regulated in *USO1*-depleted with genes that had either a positive or negative correlation co-efficient. We found a highly significant overlap between genes that were positively correlated with *USO1* across the B-ALL samples and downregulated in *USO1*-depleted cells (Hypergeometric test; $p < 0.0001$), but not in genes that were upregulated in *USO1*-depleted cells (non-significant p value) (Fig. 4F, Supplementary 5C & 5D). This suggests that *USO1* regulates gene expression in patient samples of B-ALL. As concrete examples, differentially expressed genes confirmed by RT-qPCR (Fig. 4C, D) showed a direct correlation with *USO1* expression in the ALL dataset from cBioPortal (Supplementary Fig. 6A–6D). These findings strongly suggest that *USO1* plays a role in gene regulation in human B-ALL.

USO1 inhibits the MLL-AF4-driven leukemogenesis in primary murine bone marrow cells.

Having demonstrated that *USO1* is required for the survival and growth of *MLL-AF4*⁺ cells in culture, we wanted to determine if *USO1* was required in an experimentally induced primary cell model of *MLL-AF4*-driven leukemia. Briefly, *Lin*⁻ cells from the bone marrow of *Cas9-EGFP* mice³² were transduced with *MLL-Af4* retrovirus³³ (Fig. 5A) and selected with G418. We confirmed expression of the *MLL-Af4* transgene, finding overexpression by RT-qPCR and western blot analysis (Fig. 5B). As expected, we observed rapid proliferation and expansion of the *Lin*⁻ *Cas9*^{*MLL-Af4*} cells. In order to deplete *Uso1* from these cells, we designed and cloned three *Uso1* murine specific sgRNAs (*msg2* and *msg3*) into our internally designed MSCV.EFs.mCherry retroviral vector. To determine their effectiveness, we sorted GFP⁺ mCherry⁺ 70Z/3 cells transduced with the MSCV retroviruses, briefly expanded them in culture, and then queried *USO1* expression. Western blot and RT-qPCR demonstrated that *msg2* and *msg3* both resulted in significant reduction of *USO1* protein and mRNA expression (Fig. 5C, D). *Uso1*-depleted 70Z/3 cells also had reduced cell growth by MTS assay which correlated with the different levels of *USO1* depletion for *msg2* and *msg3* (Fig. 5E). From these data, the *msg3* retrovirus was selected for transduction of *Lin*⁻ *Cas9*^{*MLL-Af4*} cells. After sorting GFP⁺ mCherry⁺ transduced *Lin*⁻ *Cas9*^{*MLL-Af4*} cells (Fig. 5F), *USO1*-depletion was confirmed by western blot, in which protein expression was reduced to 26% (Fig. 5G), and the cells were subsequently used in a colony formation assay. Functionally, *USO1*-depletion resulted in significantly fewer colonies in *Lin*⁻ *Cas9*^{*MLL-Af4*} cells compared to NT control cells at 12 days. This change was maintained at several different starting numbers of *Lin*⁻ *Cas9*^{*MLL-Af4*} cells (Fig. 5H). Hence, the function of *USO1* is preserved in not only in human B-ALL cell lines but also in primary murine *MLL-Af4* transduced cells.

Discussion

The molecular mechanism of *MLL-AF4* driven leukemogenesis remains incompletely understood, and this subtype of B-ALL is highly aggressive^{5,7}. Although there are several fusion partners for *MLL* in acute leukemia, downstream transcriptional dysregulation is a common feature^{15,34,35}. In this study, we sought to understand whether overexpression of putative RBPs, which we identified previously, contributes to the pathogenesis of *MLL-AF4*⁺ B-ALL¹⁵. We performed a focused sub-genomic CRISPR/Cas9 dropout screen to specifically address whether these putative RBPs had a functional role in leukemia cell growth. Indeed, we identified three genes (*EIF3E*, *EPRS*, and *USO1*) that appeared to be required in the *MLL-AF4*⁺ cell line, SEM. These genes showed slightly higher rates of dropout in SEM cells than in NALM6 cells. Of these, *USO1* expression showed a dependence on *MLL-AF4*, whereas *EIF3E* and *EPRS* did not show the same dependence and were previously reported to be “common essential genes”, per the depmap portal²². Follow-up studies confirmed a role for *USO1*, both in cell lines and in a model of *MLL-AF4* driven leukemia in primary murine bone marrow cells. RNA sequencing revealed that *USO1* regulates numerous pathways, including mTOR, MYC targets, as well as elements of RNA homeostasis.

One of the challenges of genomic-scale CRISPR screens is that genes with a small average effect size on the phenotype of interest can be quite difficult to identify and can frequently be “drowned out” by genes with a larger effect size³⁶. As we were particularly interested in the role that RBPs play in B-ALL, and their effect size in cell lines is unknown, we chose to perform a sub-genomic essentiality screen targeting a pre-defined set of RBPs known to be highly expressed in B-ALL. Therefore, under the hypothesis that a significant proportion of the




Figure 4. USO1 depletion significantly affects gene expression and pathways related to cell survival and proliferation. **(A)** Enrichment plots generated by the Metascape gene list enrichment analysis webtool on for the RNA-seq data from USO1-depleted versus NT control SEM cells. The top and bottom panels show pathways that are downregulated and upregulated in USO1-depleted SEM cells, respectively. **(B)** Volcano plot representing differentially expressed genes ($P_{adj} < 0.01$ and $\text{Log}_2\text{FC} > 1.5$) with several examples highlighted from the pathways enriched in **(A)**. **(C, D)** RT-qPCR validation of differentially expressed genes identified in **(B)** (t test; $*P < 0.05$; $**P < 0.01$) **(E)** Western blot showing mildly reduced expression of p-MTOR (Ser2481) expression in USO1-depleted cells, compared to NT control, while MTOR remains unchanged. **(F)** Venn diagrams showing the number of shared genes between USO1-positively correlated genes in Target-Phase II ALL dataset with the genes that are significantly upregulated (top) or downregulated (bottom) in USO1-depleted SEM cells. A hypergeometric test was utilized to compare the overlaps between the datasets using a genome size of 24,278 genes. Total and shared number of genes are indicated.




Figure 5. *USO1* depletion in transformed bone marrow cells shows reduced proliferation and colony forming potential. **(A)** Schematic of an in vitro model system to transform Lin⁻ bone marrow cells from Cas9-*egfp* mice using overexpression of *MLL-Af4* transgene in. **(B)** Analysis of overexpression of *MLL-Af4* by RT-qPCR and western blot in retrovirally transduced Lin⁻ Cas9^{MLL-Af4} cells, Lin⁻ Cas9 cells were used as negative control and 70Z/3 cells transduced with *MLL-Af4* were used as positive control. RT qPCR was performed with an optimized set of primers, normalized to L32, and represented as fold-change from an internal control for each experiment. Western blotting was performed with an antibody to *MLL1*. Vinculin was used as a high molecular weight loading control. **(C)** Upper panel, schematic of murine *UsO1* depletion experiments, showing location of sgRNAs relative to the gene, and RT-qPCR primer location. Bottom panel, western blot analysis of 70Z/3 cells transduced with three different sgRNAs targeting *UsO1* (msg1-3) cloned in the MSCV.sgRNA.mCherry.v1 vector. **(D)** RT-qPCR analysis of *UsO1* depletion in 70Z/3 cells. **(E)** MTS assay (Absorbance at 490 nm) to measure proliferation in *UsO1*-depleted 70Z/3 cells compared to NT control cells. **(F)** FACS plot showing gating schema to sort the Lin⁻ Cas9^{MLL-Af4} GFP⁺ mCherry⁺ population following transduction with the *UsO1* msg3 vector. **(G)** Western blot was used to confirm the reduction in *USO1* expression in sorted Lin⁻ Cas9^{MLL-Af4} cells. **(H)** Colony formation assay using Lin⁻ Cas9^{MLL-Af4} cells in methylcellulose assay as described in methods with titration of input cell number (t test, *** $P < 0.001$; **** $P < 0.0001$).

sgRNAs would have a negative effect on cell viability, our design included a substantial number of both positive and negative control sgRNAs in order to properly model the null effect distribution and compare the effect size of functional RBPs to that of known essential genes. Secondly, the use of a non-*MLL-AF4* control cell line allowed us to identify those proteins whose expression might be most important in *MLL-AF4* leukemia. Supporting the idea that such specific effects may not be seen in genome scale studies, *USO1* dropout was detected in one prior genome-scale analysis, whereas it was not observed in two other genome scale studies that queried vulnerabilities in *MLL*-translocated leukemia^{17,37,38}. Thus, our approach to perform this type of CRISPR/Cas9 screen may help inform the design of future forward genetic screens.

Our group is interested in understanding RNA binding proteins in B-ALL, and we recently described the functional role of *IGF2BP3* in pathologic expansions of cells within the hematopoietic system and its requirement for survival and growth in B-ALL cell lines¹⁵. Here, we focused on *USO1*, based on its identification in this screen as well as a prior study in MV-4-11 AML cells that had identified *USO1* as a factor required for AML survival¹⁷. A recent study reported a *KMT2A(MLL)*-*USO1* fusion gene in a secondary AML, hinting at a further connection between *MLL*-driven leukemia and *USO1*³⁹. More generally, *USO1* has been shown to be of functional importance in cancer^{23–25}. *USO1* was recently reported to have RNA-binding function in studies utilizing high-throughput biochemical techniques^{16,40,41}, despite a canonical role in the regulation of vesicular transport^{42,43}. Adding to these prior descriptions of *USO1* function, we validated *USO1* as a *MLL-AF4*-induced gene, and found that it was functionally required in cell lines and in primary bone marrow for *MLL-AF4* dependent phenotypes. This work firmly establishes the significance of this protein in acute leukemia, which was not previously appreciated.

Recent studies in multiple myeloma have shown that *USO1*-deficient cells showed have reduced cell proliferation and increased apoptosis via regulation of Erk pathway activity²⁴. Transcriptome analysis of *USO1*-depleted SEM cells in our study demonstrated a mixed picture, with the downregulation of certain cancer and cell growth-related pathways, including *mTOR* and *ERB2*, but concurrent downregulation of RNA metabolism and *MYC* targets. Curiously, there was also upregulation of the *mTORC1* hallmark pathway in *USO1*-depleted cells (as opposed to downregulation of *mTOR* generally), perhaps indicating a specific effect on *mTORC2*. Nonetheless, we observed decreased phospho-*mTOR*, which is consistent with the effect seen on cell growth and cell cycle. Additionally, our data suggests that *USO1* is associated with other molecular functions of gene regulation, such as RNA homeostasis. Interestingly, the pathways noted to be deregulated show similarity to those deregulated upon inhibition of the RNA demethylase *FTO*⁴⁴. It is important to note, however, that we have not characterized its function as a RBP. It is tempting to speculate that *USO1* is a bifunctional protein with roles in vesicular transport and RNA binding, perhaps in a manner similar to *YBX1*⁴⁵. *YBX1* appears to bind to and sort microRNAs, specifically, miR-223, into exosomes. By regulating this process, *YBX1* can impact cellular homeostasis. Hence, further work to assess the molecular role of *USO1* as a putative RBP in *MLL-AF4* translocated leukemia is warranted.

Overall, our study successfully queried the functional relevance of a set of genes identified from primary patient samples using expression profiling. Here, we provide a rubric for how to functionally analyze a prioritized list of genes in leukemogenesis, or in other pathogenetic processes. In addition, we establish a role for the putative RBP, *USO1*, in leukemogenesis. Given the broader range of cancer types that show *USO1* dysregulation, our work may have implications beyond those in B-ALL. Furthermore, understanding how non-canonical RBP may participate in leukemogenesis may open up new avenues in developing novel strategies for the diagnosis, prognosis, and treatment of B-ALL.

Methods

Cell lines and cell culture. All the cell lines involved in the study were maintained at 37 °C in a humidified incubator at 5% CO₂. RS4;11 (ATCC CRL-1873), NALM6 (ATCC CRL-3273) were cultured in RPMI 1640 supplemented with 10% FBS. 70Z/3 (ATCC TIB 158) cells were cultured in RPMI 1640 supplemented with 10% FBS and 0.05 mM 2-mercaptoethanol. SEM cells (DMZ-ACC 546), MV-4-11 (ATCC CRL-9591) were cultured in Iscove's Modified Dulbecco's Medium (IMDM) supplemented with 10% FBS. Mouse bone marrow derived Lineage (Lin⁻) cells were cultured in IMDM media supplemented with 15% FBS, 20 ng/mL mTPO, 20 ng/FLT3 ligand and 50 ng/mL mSCF.

Sub-genomic CRISPR screen. A sub-genomic CRISPR/Cas9 screen was designed to target 36 RBP genes and 12 “positive control genes”, and included 28 negative control (or non-targeting) single guide RNAs (sgRNAs). The positive control genes, representing known vulnerabilities in *MLL*-translocated acute leukemia, were selected from top 100 genes dysregulated in Genome wide CRISPR screen in MV-4-11 cells¹⁷. These genes are expected to “drop out” in a CRISPR screen of *MLL*-translocated leukemia, but it is not known whether they are specific for *MLL*-translocated leukemia. This design was adapted to provide enough non-targeting controls in the context of a sub-genomic screen, where a significant proportion of targeting sgRNAs may be expected to change. Five sgRNAs were designed for each RBP or positive control genes, using sgRNA design tools from Broad Institute⁴⁶. pLKO5.sgRNA.EFS.tRFP is a lentiviral vector, which contains EF-1 alpha binding sequence (EFS) upstream of tRFP, was obtained from Addgene (#57,823)⁴⁷. The 268 pooled sgRNA were then cloned into pLKO5.sgRNA.EFS.tRFP lentiviral vector using standard protocols¹⁷. Prior to CRISPR/Cas9 screening, B-ALL cell lines with *MLL-AF4* translocation (SEM)³³ and without *MLL-AF4* translocation (NALM6)⁴⁸ were stably transduced with pLentiCas9-GFP⁴⁹ lentivirus and sorted on GFP positivity, with subsequent confirmation of Cas9 expression (Supplementary Fig. 1A). pLKO5.sgRNA.EFS.tRFP lentiviral pool titers were calculated from SEM and NALM6 cell transduction. For experiments, bulk GFP⁺ SEM and NALM6 cells were infected at <0.3 MOI and 2 × 10⁶ cells GFP⁺ tRFP⁺ were sorted by FACS after 48 h of infection (Supplementary Fig. 1B). Genomic DNA (gDNA) isolated from 10⁶ cells was used for construction of the Reference (REF) library sample, and

the other 10^6 cells were cultured and expanded. Cells were split every five days and 10^6 cells were reseeded for culture⁵⁰ to maintain a sgRNA representation of 3700X. Following 28 days of culture, cells were harvested and gDNA was isolated for the Depletion (DEP) library sample preparation.

Library preparation, DNA sequencing, and analysis. Sequencing libraries were prepared from both the Reference (REF) and Depleted (DEP) genomic DNA (gDNA) samples obtained at days 0 and 28 of CRISPR screen experiment, respectively^{17,50}. Libraries were prepared from 200 ng of input DNA, by using Q5 high-fidelity DNA polymerase (#M0492S, NEB) and Illumina adapted primers to amplify the sgRNA target region from the gDNA, as previously described¹⁷ (Supplementary Fig. 1C). The purified PCR product was quantified using Qubit and quality control was done using Bioanalyzer and sequenced on HiSeq 3000 at the Technology Center for Genomic and Bioinformatics at UCLA. Adapter sequences were removed using in-house scripts. Candidate reads (those containing a valid primer sequence and with a minimum length of 20 bp after trimming) were aligned to the sgRNA library using bowtie v0.12.8⁵¹ with a maximum tolerance of one mismatch. Counts tables for both individual sgRNAs and gene-level summaries were compiled from non-ambiguous hits for both the Reference and Depletion libraries in each experiment and for each cell line. Count tables were processed with DESeq2⁴⁸ to obtain variance-stabilized normalized abundance and rank sgRNAs and genes based on differential abundance (moderated fold change and adjusted Wald test p value).

Cell line treatment with transcription inhibitors. B-ALL cell lines were plated at 0.5×10^6 cells/mL density 24 h before treatment, and harvested 48 h after initiating treatment with the chemical inhibitor. I-BET151, a BRD4 inhibitor was reconstituted in DMSO (10 mM), was diluted in complete media and added to the cells at a concentration of 0.5 μ M, 1.0 μ M and 2.0 μ M. MI-503, a menin-MLL inhibitor, was used to treat the cells at 0.12 μ M, 0.25 μ M and 0.5 μ M. EPZ5676, a DOT1L inhibitor, was used to treat cells at a concentration of 0.5 μ M of EPZ5676.

Cell proliferation, cell cycle and apoptosis assays. Cell proliferation assay was performed using standard MTS assay protocol. 5000 cells were plated in 100 μ L volume of media in a single well of 96-well tissue culture plates. Cells were harvested at different time points of day 0, day1, day 3 and day 5. MTS reagent mix was prepared by adding 100 μ L of PMS solution (0.21 mg/mL) to 1 ml of MTS reagent (0.33 mg/mL) and 20 μ L reagent mix was added to each well. The plate was incubated at 37 °C for 2 h and absorbance was taken at 490 nm in a microplate reader.

Cell cycle analysis was performed using propidium iodide (PI). Cells were harvested and washed in PBS and fixed in 70% ethanol overnight at -20 °C. Fixed cells were washed with PBS and centrifuged at 2500 rpm. PI solution (2 mg/10 mL) was diluted in PBS and added with 0.2 mg/mL of DNase free RNase A. Nearly, 300 μ L of the PI solution was added to each tube and incubated at RT for 2 h. The stained samples were analyzed by flow cytometer.

Annexin V staining was performed to study the apoptosis in the cells using standard protocol. Briefly, cells treated with inhibitors/siRNAs were harvested and washed in PBS before resuspending in binding buffer (10⁶/mL). 100 μ L of cell suspension was stained with 0.5 μ L of Annexin V antibody conjugated to Pacific blue and incubated at RT for 30 min. After incubation, 300 μ L of binding buffer was added to the sample and analyzed by flow cytometer.

siRNA knockdown of cell lines. siRNA transfection was performed using standard Nucleofection program provided by the manufacturer. SEM cells were Nucleofected using the 4D Nucleofector System (Lonza, Cologne, Germany). Cells were washed with phosphate-buffered saline and then resuspended in nucleofection solution (SF Cell Line 4D-Nucleofector X Kit, Lonza, Cologne, Germany), at a final concentration of 2×10^6 cells/100 μ L reaction. Cells were nucleofected with 30 pmol of control siRNA, USO1 siRNA1, or USO1 siRNA 4, in 100 μ L cuvettes using program CV-104. Immediately after nucleofection, 500 μ L of pre-warmed, antibiotic-free media was added to the cuvette and incubated for 10 min at RT. After incubation cells were transferred to a 12 well plate containing 1.5 mL of media. Nucleofected cells were maintained at 37 °C and 5% CO₂ prior to harvesting for analysis.

RT-qPCR assays. Previous protocols were adapted for RT-qPCR, based on our prior work¹⁵. A full list of RT-qPCR primers is presented in Table S2. For normalization, we utilized RT-qPCR primers for 18S (human) and L32 (mouse).

Western Blotting. Western Blotting was performed as previously described¹⁵. The blots were developed and imaged on ECL film or on a Bio-Rad Chemidoc digital imager using Super signal West Pico PLUS chemiluminescent reagent. EPRS (#A303-957A), EIF3E (#A302-984A), USO1 (#A304-513A) antibodies were purchased from Bethyl laboratories. USO1 (13,509-1-AP) antibody to detect mouse USO1 was purchased from Proteintech. MTOR (#2972 s) and Phospho-MTOR (Ser2481) (#2971) antibodies were procured from Cell Signaling Technology. Vinculin (Santa Cruz Biotechnology, # sc-73614) and Anti- β -Actin (Sigma Aldrich, #A1978) were used for loading controls.

Chromatin immunoprecipitation (ChIP). SEM cells were cultured with and without I-BET151 (Sigma Aldrich, # SML0666) and DMSO for 48 h at 37 °C⁵². ChIP was performed using EZ-Magna ChIP kit (Millipore,

17–408) with MLL1 antibody (Bethyl laboratories, #A300-374A) and AF4 antibody (Abcam, #ab31812). The purified DNA was used as input for qPCR and binding was quantitated as previously described⁵².

Immortalization of Lin⁻ bone marrow cells. All mice used in this study were obtained from Jackson Labs and were genotyped according to JAX protocols and maintained in the UCLA Division of Laboratory Animal Medicine. Bone marrow cells from C57BL6/J *Cas9-EGFP* mice⁵³ (Jackson Laboratories, # 026,179) were isolated by flushing the bones from the mice and creating a single cell suspension. Cells were incubated with a lineage antibody cocktail and depleted for Lineage⁺ cells using MACS technology (Miltenyi Biotech). Lin⁻ cells were spin-infected and transduced with *MLL-Af4* retroviral preparation³³. The MSCV-MLL-flag-Af4 plasmid was the kind gift via MTA by Dr. Michael Thirman (University of Chicago, Department of Medicine). After four rounds of transduction, cells were selected in 400 µg/mL G418 supplemented media for 7 days.

MSCV sgRNA vectors. We generated a novel MSCV vector that can overexpress an individual sgRNA in addition to an mCherry reporter. In brief, the MSCV.mU6.sgRNA-EFs.mCherry.v1 retroviral vector was constructed by replacing a 2.1 kb EGFP-PGK.Puro fragment from the pMGP vector with a 2.7 kb sequence containing mU6.BbsI-stuffer-BbsI-scaffold-spacer-EFs.mCherry via BglII/ClaI digest. The sgRNA scaffold and EF-1α short (EFs) promoter elements were derived from the pLentiCRISPRv2 vector. The mU6 promoter was designed from the GenBank sequence NC_000076.6 (nt 79,908,880–79,909,195). A silent mutation was incorporated into the mCherry reporter element to remove an internal BbsI restriction site. The 1.2 kb stuffer sequence was derived from portions of the 1.8 kb firefly luciferase gene. The sgRNA sequences targeting mouse were designed as above and directionally cloned between the mU6 promoter and sgRNA scaffold sequence via BbsI. Detailed methods and vector maps are available upon request.

Colony forming unit assay. A colony forming unit assay was performed to study the effect of *USO1*-depletion on the colony forming potential of Lin⁻Cas9^{MLL-Af4} cells. The assay was performed using the Methocult colony forming media (STEMCELL Technologies, #M3434)⁵⁴. Briefly, approximately 5,000 Lin⁻Cas9^{MLL-Af4} *USO1* depleted cells were mixed in 3.2 ml of overnight thawed Methocult media and plated in two 35 mm dishes along with the NT controls and cultured for 12 days. After 12 days of culture, individual 35 mm dishes were counted for both total number and morphologic subtypes of colonies formed by *USO1* depletion and NT control cells.

RNA-Seq library preparation and analysis. Libraries for RNA-Seq were prepared with Nugen Universal plus mRNA-Seq Kit to generate strand-specific RNA-seq libraries. Sequencing was performed on Illumina HiSeq 3000 SR 1 × 50 bp run. Data quality check was done on Illumina SAV. Demultiplexing was performed with Illumina Bcl2fastq2 v 2.19.1.403 program. The STAR ultrafast universal RNA-seq aligner v2.7.0d⁵⁵ was used to align the reads to a genome index that included both the genome sequence (GRC38 human primary assembly) and the exon/intron structure of known human gene models (Gencode v29 genome annotation). Alignment files were used to generate strand-specific, gene-level count summaries with STAR's built-in gene counter. Independent filtering was applied as before^{56,57}: genes with less than 6 total counts across all samples, count outliers, or low mappability (< 50 bp) were filtered out for downstream analyses. Expression estimates were computed in units of fragments per kilobase of mappable length and million counts (FPKMs). Differential expression analyses between *USO1* depletion and non-targeted controls was performed with DESeq2²⁷ and genes were ranked based on moderated fold change and adjusted Wald test p value. Functional enrichment for selected genes was performed with Metascape³⁶.

Approvals and Compliance. This study was carried out in compliance with the ARRIVE guidelines. All animal experiments were carried out in accordance with relevant guidelines governing the use of animals in research. In addition, all experiments involving animals were approved by the University of California, Los Angeles, Chancellor's Animal Research Committee (ARC), which was established for compliance with Public Health Service (PHS) guidelines on animal research.

Data availability

All sequencing data have been deposited in the Sequence Read Archive (PRJNA658354). All research materials will be made available in accordance with UCLA policy.

Received: 13 December 2020; Accepted: 10 June 2021

Published online: 23 June 2021

References

- Mullighan, C. G. Molecular genetics of B-precursor acute lymphoblastic leukemia. *J. Clin. Invest.* **122**(10), 3407–3415 (2012).
- Takeuchi, S. *et al.* TEL is one of the targets for deletion on 12p in many cases of childhood B-lineage acute lymphoblastic leukemia. *Leukemia* **11**(8), 1220–1223 (1997).
- Luong-Gardioli, N. *et al.* Gamma-catenin-dependent signals maintain BCR-ABL1(+) B cell acute lymphoblastic leukemia. *Cancer Cell* **35**(4), 649–663 (2019).
- Stong, R. C., Korsmeyer, S. J., Parkin, J. L., Arthur, D. C. & Kersey, J. H. Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. *Blood* **65**(1), 21–31 (1985).
- Dreyer, Z. E. *et al.* Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: A report from the Children's Oncology Group. *J. Clin. Oncol.* **29**(2), 214–222 (2011).

6. Behm, F. G. *et al.* Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. *Blood* **87**(7), 2870–2877 (1996).
7. Hilden, J. M. *et al.* Analysis of prognostic factors of acute lymphoblastic leukemia in infants: Report on CCG 1953 from the Children's Oncology Group. *Blood* **108**(2), 441–451 (2006).
8. Moorman, A. V. *et al.* Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: Results from the UK Medical Research Council ALL97/99 randomised trial. *Lancet Oncol.* **11**(5), 429–438 (2010).
9. Witkowski, M. T. *et al.* Conserved IKAROS-regulated genes associated with B-progenitor acute lymphoblastic leukemia outcome. *J. Exp. Med.* **214**(3), 773–791 (2017).
10. Miglino, M. *et al.* Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): Predictive role of minimal residual disease monitoring on relapse. *Bone Marrow Transplant.* **30**(9), 579–585 (2002).
11. Prasad, V. Immunotherapy: Tisagenlecleucel—The first approved CAR-T-cell therapy: implications for payers and policy makers. *Nat. Rev. Clin. Oncol.* **15**(1), 11–12 (2018).
12. Gokbuget, N. *et al.* Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. *Blood* **131**(14), 1522–1531 (2018).
13. Turtle, C. J. *et al.* CD19 CAR-T cells of defined CD4+CD8+ composition in adult B cell ALL patients. *J. Clin. Invest.* **126**(6), 2123–2138 (2016).
14. Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. *Cancer Discov.* **8**(10), 1219–1226 (2018).
15. Palanichamy, J. K. *et al.* RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation. *J. Clin. Invest.* **126**(4), 1495–1511 (2016).
16. Castello, A. *et al.* Comprehensive identification of RNA-binding domains in human cells. *Mol. Cell.* **63**(4), 696–710 (2016).
17. Wallace, J. *et al.* Genome-wide CRISPR-Cas9 screen identifies microRNAs that regulate myeloid leukemia cell growth. *PLoS ONE* **11**(4), e0153689 (2016).
18. Dawson, M. A. *et al.* Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. *Nature* **478**(7370), 529–533 (2011).
19. Borkin, D. *et al.* Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. *Cancer Cell* **27**(4), 589–602 (2015).
20. Daigle, S. R. *et al.* Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. *Blood* **122**(6), 1017–1025 (2013).
21. Lin, S. *et al.* Instructive role of MLL-fusion proteins revealed by a model of t(4;11) Pro-B acute lymphoblastic leukemia. *Cancer Cell* **30**(5), 737–749 (2016).
22. Tsherniak, A. *et al.* Defining a cancer dependency map. *Cell* **170**(3), 564–76.e16 (2017).
23. Sui, J. *et al.* Lentivirus-mediated silencing of USO1 inhibits cell proliferation and migration of human colon cancer cells. *Med. Oncol.* **32**(8), 218 (2015).
24. Jin, Y. & Dai, Z. USO1 promotes tumor progression via activating Erk pathway in multiple myeloma cells. *Biomed. Pharmacother.* **78**, 264–271 (2016).
25. Howley, B. V., Link, L. A., Grelet, S., El-Sabban, M. & Howe, P. H. A CREB3-regulated ER-Golgi trafficking signature promotes metastatic progression in breast cancer. *Oncogene* **37**(10), 1308–1325 (2018).
26. Sentmanat, M. F., Peters, S. T., Florian, C. P., Connelly, J. P. & Pruett-Miller, S. M. A survey of validation strategies for CRISPR-Cas9 editing. *Sci. Rep.* **8**(1), 888 (2018).
27. Zhou, Y. *et al.* Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. *Nat. Commun.* **10**(1), 1523 (2019).
28. Subramanian, A. *et al.* Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. USA* **102**(43), 15545–15550 (2005).
29. van Riggelen, J., Yetil, A. & Felsher, D. W. MYC as a regulator of ribosome biogenesis and protein synthesis. *Nat. Rev. Cancer.* **10**(4), 301–309 (2010).
30. Cerami, E. *et al.* The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* **2**(5), 401–404 (2012).
31. Gao, J. *et al.* Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci. Signal.* **6**(269), 11 (2013).
32. Platt, R. J. *et al.* CRISPR-Cas9 knockin mice for genome editing and cancer modeling. *Cell* **159**(2), 440–455 (2014).
33. Lin, S., Luo, R. T., Shrestha, M., Thirman, M. J. & Mulloy, J. C. The full transforming capacity of MLL-Af4 is interlinked with lymphoid lineage commitment. *Blood* **130**(7), 903–907 (2017).
34. Xia, Z. B. *et al.* The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression. *Proc. Natl. Acad. Sci. USA* **102**(39), 14028–14033 (2005).
35. Andersson, A. K. *et al.* The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. *Nat. Genet.* **47**(4), 330–337 (2015).
36. Bodapati, S., Daley, T. P., Lin, X., Zou, J. & Qi, L. S. A benchmark of algorithms for the analysis of pooled CRISPR screens. *Genome Biol.* **21**(1), 62 (2020).
37. Tzelepis, K. *et al.* A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia. *Cell Rep.* **17**(4), 1193–1205 (2016).
38. Erb, M. A. *et al.* Transcription control by the ENL YEATS domain in acute leukaemia. *Nature* **543**(7644), 270–274 (2017).
39. Jin, W. *et al.* A novel KMT2A-USO1 fusion gene-induced de novo secondary acute myeloid leukaemia in a patient initially diagnosed with acute promyelocytic leukaemia. *Br. J. Haematol.* **192**, e32–e36 (2021).
40. Castello, A. *et al.* Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. *Cell* **149**(6), 1393–1406 (2012).
41. Beckmann, B. M. *et al.* The RNA-binding proteomes from yeast to man harbour conserved enigmRBPs. *Nat. Commun.* **6**, 10127 (2015).
42. Nakamura, N., Lowe, M., Levine, T. P., Rabouille, C. & Warren, G. The vesicle docking protein p115 binds GM130, a cis-Golgi matrix protein, in a mitotically regulated manner. *Cell* **89**(3), 445–455 (1997).
43. Allan, B. B., Moyer, B. D. & Balch, W. E. Rab1 recruitment of p115 into a cis-SNARE complex: Programming budding COPII vesicles for fusion. *Science* **289**(5478), 444–448 (2000).
44. Huang, Y. *et al.* Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia. *Cancer Cell* **35**(4), 677–691 (2019).
45. Shurtleff MJ, Temoche-Diaz MM, Karfilis KV, Ri S, and Schekman R. Y-box protein 1 is required to sort microRNAs into exosomes in cells and in a cell-free reaction. *Elife.* **5**, e19276 (2016).
46. Doench, J. G. *et al.* Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. *Nat. Biotechnol.* **34**(2), 184–191 (2016).
47. Heckl, D. *et al.* Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. *Nat. Biotechnol.* **32**(9), 941–946 (2014).
48. Benito, J. M. *et al.* MLL-Rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199. *Cell Rep.* **13**(12), 2715–2727 (2015).
49. Wang, S. *et al.* Enhancement of LIN28B-induced hematopoietic reprogramming by IGF2BP3. *Genes Dev.* **33**(15–16), 1048–1068 (2019).
50. Doench, J. G. Am I ready for CRISPR? A user's guide to genetic screens. *Nat. Rev. Genet.* **19**(2), 67–80 (2018).

51. Langmead B. Aligning short sequencing reads with Bowtie. *Curr. Protoc. Bioinform.* 2010; Chapter 11:Unit 11.7.
52. Ptasińska, A. *et al.* Identification of a dynamic core transcriptional network in t(8;21) AML that regulates differentiation block and self-renewal. *Cell Rep.* **8**(6), 1974–1988 (2014).
53. LaFleur, M. W. *et al.* A CRISPR-Cas9 delivery system for in vivo screening of genes in the immune system. *Nat. Commun.* **10**(1), 1668 (2019).
54. McKenzie, M. D. *et al.* Interconversion between tumorigenic and differentiated states in acute myeloid leukemia. *Cell Stem Cell* **25**(2), 258–272 (2019).
55. Dobin, A. *et al.* STAR: Ultrafast universal RNA-seq aligner. *Bioinformatics* **29**(1), 15–21 (2013).
56. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**(12), 550 (2014).
57. Casero, D. *et al.* Long non-coding RNA profiling of human lymphoid progenitor cells reveals transcriptional divergence of B cell and T cell lineages. *Nat. Immunol.* **16**(12), 1282–1291 (2015).

Acknowledgements

We thank Drs. Jayanth Palanichamy and Jennifer King for helpful discussions and technical assistance with experiments performed herein. This work was supported by the NIH/NCI R01CA166450 (D.S.R), NIH/NCI R03CA251845 (D.S.R), NIH/NIAID R21AI132869 (D.S.R), Tumor Cell Biology Training Grant T32 CA009056 (T.M.T.), Tumor Immunology Training Grant T32CA009120 (T.L.L.), , and a grant from the Margaret E. Early Trust (D.S.R.). Flow cytometry was performed in the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research UCLA Flow Cytometry Core Resource and the UCLA JCCC/CFAR Flow Cytometry Core Facility that is supported by NIH AI-28697, P30CA016042, the JCCC, the UCLA AIDS Institute, and the David Geffen School of Medicine at UCLA. The results published here are in part based upon data generated by the Therapeutically Applicable Research to Generate Effective Treatments (<https://ocg.cancer.gov/programs/target>) initiative, phs000218. The data used for this analysis are available at <https://portal.gdc.cancer.gov/projects>.

Author contributions

A.K.J.: Experimental Design, Experimentation, Data Analysis and Interpretation, Manuscript Preparation. H.T., T.L.L.: Experimentation, Data Analysis and Interpretation. T.M.T.: Experimentation, Data Analysis and Interpretation, Manuscript Preparation. D.C.: Data Analysis and Interpretation. M.O.A.: Experimentation. D.S.R.: Experimental Design, Data Analysis and Interpretation, Manuscript Preparation, Funding.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-021-92448-w>.

Correspondence and requests for materials should be addressed to D.S.R.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021